Published in Hepatitis Weekly, November 28th, 2005
"ADV, a new nucleotide analogue, has demonstrated activity against lamivudine-resistant HBV both in vivo and in vitro. Herein, we present eight lamivudine-resistant patients with chronic anti-HBe positive hepatitis B treated orally with adefovir dipivoxil at 10 mg/day to evaluate the efficacy and safety of this drug and to determine the possible development of clinical ADV resistance," wrote G. Scotto and colleagues, University of Foggia.
"After 48 weeks of therapy, 4/8 (50%)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.